Abstract Number: 0443 • ACR Convergence 2023
The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis
Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…Abstract Number: 2142 • ACR Convergence 2023
Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors
Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…Abstract Number: 2507 • ACR Convergence 2023
ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…Abstract Number: 0542 • ACR Convergence 2023
Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…Abstract Number: 2541 • ACR Convergence 2023
Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…Abstract Number: 0775 • ACR Convergence 2022
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
Background/Purpose: The development of new autoantibodies and secondary autoimmunity is a common and significant side effect of TNF inhibitors (TNFi) which are widely used to…Abstract Number: 1159 • ACR Convergence 2022
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…Abstract Number: 1600 • ACR Convergence 2022
The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: While evidence in patients (pts) with RA suggests that switching to a therapy with a different mechanism of action (MOA) may be more effective…Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…Abstract Number: 1622 • ACR Convergence 2022
TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Background/Purpose: We previously demonstrated that TNF-transgenic (TNF-Tg) mice have findings consistent with connective-tissue disease associated pulmonary arterial hypertension (CTD-PAH), and that this pathology is mediated…Abstract Number: 2192 • ACR Convergence 2022
Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »